Novo Nordisk shares fell 8% after Eli Lilly reported positive trial results for its weight loss drug, orforglipron, affecting the healthcare sector. Novo Nordisk's shares dropped t...
Novo Nordisk shares fell 8% after Eli Lilly revealed positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's shares saw a slight ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's stock rose slightly...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug, orforglipron, impacting the healthcare sector. Novo Nordisk's shares dropped ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive late-stage trial results for its oral weight loss drug, orforglipron, impacting the healthcare sector and Novo Nordis...
